Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Ashraf Raslan, MD, Dorian Infantino, MD, Roman Zuckerman, DO, & Daniel Berlin, MD  |  Issue: November 2021  |  November 14, 2021

The biopsy of the left temporal artery with elastin staining shows disruption of the internal elastic lamina.

Figure 4. The biopsy of the left temporal artery with elastin staining shows disruption of the internal elastic lamina.

Giant cell arteritis is the most common form of systemic vasculitis in North America and can lead to serious complications if not diagnosed promptly and treated appropriately. The classic presentation is of new-onset temporal headaches (usually unilateral) along with jaw claudication and/or proximal myalgias and arthralgias in a patient over the age of 50.

The clinical suspicion is usually confirmed by markedly elevated inflammatory markers and a rapid response to high-dose steroids. Temporal artery biopsy is the gold standard to confirm the diagnosis, but clinical suspicion of GCA is enough to commence steroid treatment to avoid the dreaded complication of vision loss.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Occasionally, atypical presentations present challenges in diagnosis and management. Our case highlights some of these challenges, and we offer some clinical pearls. Consider:

The type of headache

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The main feature is that the headache is new.

Many clinicians associate GCA with severe temporal headaches associated with scalp tenderness. In practice, the headache location is variable and can be frontal, temporal, parietal, occipital or generalized.1 The headache phenotype is also nonspecific. It can have features of a tension or migraine headache. On occasion, GCA can present without headaches, making the diagnosis even more difficult.

Uncommon presenting symptoms

Consider GCA in a patient who presents with oculomotor palsy.2-4

In this case, the patient presented to us with headache and diplopia due to a pupil-involving, partial third nerve palsy. Oculomotor nerve palsies have been uncommonly described in patients with GCA, and pupillary involvement is even rarer. Pupillary involvement usually signifies a compressive lesion of the third nerve because the pupillary fibers lie on the periphery of the nerve. Nerve ischemia related to GCA is thought to typically affect the center of the nerve more than the periphery.4

Examples of other uncommon presenting symptoms include posterior circulation strokes, upper respiratory tract symptoms, tongue pain and tongue necrosis, mesenteric ischemia and pericarditis.5,6

Temporal artery biopsy

Perform unilateral vs. bilateral temporal artery biopsies when GCA is suspected.

The new guideline for the management of GCA, from the ACR in concert with the Vasculitis Foundation, recommends initially pursuing a unilateral temporal artery biopsy over bilateral biopsies. The recommendation is to proceed with a contralateral biopsy if the initial unilateral biopsy is negative and additional evidence for GCA diagnosis is sought.7

A recent meta-analysis of 32 studies published during 1993–2017 estimated the sensitivity of the temporal artery biopsy at 77%. The sensitivity was even lower (68%) for studies published after 2012.8 We are concerned that in clinical practice the treating physician will often have to face the difficult decision of whether to perform the contralateral biopsy if the unilateral biopsy result is unrevealing.

In our patient, although the biopsy of the symptomatic side was normal, the biopsy of the asymptomatic side demonstrated the pathology of GCA. Although the superficial temporal artery on the symptomatic side was likely affected, GCA involvement of the arteries is known to be segmental rather than contiguous and biopsy of a portion of an artery can result in sampling error. The same vascular surgeon performed both biopsies, and the same technique was used.

Similar discordant findings in bilateral temporal artery biopsy results have been reported in previous studies.9,10 For this reason, it is still not uncommon in practice for physicians to request bilateral biopsies up front.

It is crucial to remember that an unrevealing temporal artery biopsy does not rule out GCA. If compelling evidence supports a diagnosis of GCA, then treatment should be continued.

Imaging

Vascular imaging can be useful to aid in the diagnosis of GCA.11

Many studies have shown imaging can be helpful in diagnosing GCA with relatively high sensitivity and specificity, but imaging is still not widely utilized in the evaluation and diagnosis of GCA. Color Doppler ultrasound of the temporal arteries is promising and is considered the first-line imaging modality for GCA diagnosis, but the operator-dependent nature limits its use at this point outside large academic centers.

Positron emission tomography (PET) scan and MR angiography with contrast can demonstrate signs of vasculitis in the temporal arteries and aid in the diagnosis of GCA with high sensitivity and specificity, but factors including cost, availability, the need for contrast (in the case of MR) and radiation exposure (in the case of PET scan) limit their use.

In our patient, CTA of head and neck showed irregularities of the external carotid arteries that increased our suspicion for GCA.

Always consider performing bilateral temporal artery biopsies when GCA is suspected.

High-dose, long-term steroids

Consider tocilizumab as a steroid-sparing agent.8

Although corticosteroids are an extremely effective treatment for GCA, their use is frequently limited by multiple short- and long-term adverse effects. Our patient developed severe insomnia and facial swelling early on that markedly affected her quality of life. Additionally, as is the case in many patients, our patient’s symptoms resurfaced in the midst of two attempts to wean her steroid dosage. After tocilizumab was started, we were able to taper the steroids without recurrence of symptoms.

Tocilizumab should be a first-line agent, along with steroids, to limit steroid exposure, and it could be especially helpful in certain patients with comorbid conditions, such as diabetes, osteoporosis or congestive heart failure.


Ashraf Raslan, MDAshraf Raslan, MD, completed his rheumatology fellowship at Rutgers University, New Brunswick, N.J., and is a practicing rheumatologist with Valley Medical Group, Ridgewood, N.J.

 

Dorian Infantino, MDDorian Infantino, MD, has been a fellow of the American College of Pathologists since 2017 and is an anatomic and clinical pathologist with The Valley Hospital, Ridgewood, N.J.

 

Roman Zuckerman, DORoman Zuckerman, DO, is a rheumatologist at The Valley Health System, Ridgewood, N.J., with an interest in vasculitides.

 

Daniel Berlin, MDDaniel Berlin, MD, is a neurologist with subspecialty training in electromyography. He currently sees patients in Ridgewood, N.J.

 

References

  1. Tanganelli P. Secondary headaches in the elderly. Neurol Sci. 2010 Jun;31(Suppl 1):S73–S76.
  2. Walters B, Lazic D, Ahmed A, Yiin G. Lesson of the month 4: Giant cell arteritis with normal inflammatory markers and isolated oculomotor palsy. Clin Med (Lond). 2020 Mar;20(2):224–226.
  3. Thurtell MJ, Longmuir RA. Third nerve palsy as the initial manifestation of giant cell arteritis. J Neuroophthalmology. 2014 Sep;34(3):24–245.
  4. Davies GE, Shakir RA. Giant cell arteritis presenting as oculomotor nerve palsy with pupillary dilatation. Postgrad Med J. 1994 Apr;70(822):298–299.
  5. Imran TF, Helfgott S; Respiratory and otolaryngologic manifestation of giant cell arteritis. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S164–S170.
  6. Sujobert P, Fardet L, Marie I, et al. Mesenteric ischemia in giant cell arteritis: 6 cases and a systemic review. J Rheumatol. 2007 Aug;34(8):1727–1732.
  7. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1071–1078.
  8. Rubenstein E, Maldini M, Gonzalez-Chiappe S, et al. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: A systematic literature review and meta-analysis. Rheumatology (Oxford). 2020 May 1;59(5):1011–1020.
  9. Breuer G, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009 Apr;36(4):794–796.
  10. Durling B, Toren A, Patel V, et al. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol. 2014 Apr;49(2):157–161.
  11. Serling-Boyd N, Stone JH. Recent advances in the diagnosis and management of giant cell arteritis. Curr Opin Rheumatol. 2020 May;32(3):201–207.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:case reportGiant Cell Arteritistocilizumab

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Experts Discuss Proposed Giant Cell Arteritis Risk Tool

    April 26, 2018

    A proposed model to predict the risk of giant cell arteritis (GCA) prior to a temporal artery biopsy could help triage patients and guide decision making about the need for biopsy or monitoring (see Figure 1). There’s no specific biomarker for GCA, and GCA can be a “diagnostic conundrum, especially when it presents in an…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Giant Cell Arteritis Challenging to Diagnose, Manage

    March 1, 2015

    Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences